TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Detection of TNFAIP3 gene expression by real time PCR..
- Who it may be relevant to
- Registry conditions: Ankylosing Spondylitis and Psoriatic Arthritis Patients. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity. Inclusion criteria: 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11). b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Interventions
- Diagnostic test Detection of TNFAIP3 gene expression by real time PCR.
Detection of TNFAIP3 gene expression by real time PCR.
Primary outcome measures
- Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors . [Time frame: 18 months]
Secondary outcome measures (1)
- Detect relation between TNFAIP3 and ankylosing spondylitis apsoriatic arthritis activity. detection of TNFAIP3 gene expression by real time PCR will be done for every subject. [Time frame: 20 months]
Eligibility criteria
Inclusion criteria
\- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984.
2\. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)
Exclusion criteria
- Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double blind
- Primary purpose
- Diagnostic
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07507487 · TNFAIP3 gene expression